1. Home
  2. XYZ vs RMD Comparison

XYZ vs RMD Comparison

Compare XYZ & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XYZ
  • RMD
  • Stock Information
  • Founded
  • XYZ 2009
  • RMD 1989
  • Country
  • XYZ United States
  • RMD United States
  • Employees
  • XYZ N/A
  • RMD N/A
  • Industry
  • XYZ
  • RMD Medical/Dental Instruments
  • Sector
  • XYZ
  • RMD Health Care
  • Exchange
  • XYZ NYSE
  • RMD Nasdaq
  • Market Cap
  • XYZ 33.4B
  • RMD 36.7B
  • IPO Year
  • XYZ 2015
  • RMD 1995
  • Fundamental
  • Price
  • XYZ $69.01
  • RMD $255.54
  • Analyst Decision
  • XYZ Buy
  • RMD Buy
  • Analyst Count
  • XYZ 32
  • RMD 12
  • Target Price
  • XYZ $72.21
  • RMD $259.40
  • AVG Volume (30 Days)
  • XYZ 6.6M
  • RMD 749.4K
  • Earning Date
  • XYZ 07-31-2025
  • RMD 07-31-2025
  • Dividend Yield
  • XYZ N/A
  • RMD 0.83%
  • EPS Growth
  • XYZ 563.02
  • RMD 37.08
  • EPS
  • XYZ 4.12
  • RMD 8.91
  • Revenue
  • XYZ $23,935,721,000.00
  • RMD $5,021,529,000.00
  • Revenue This Year
  • XYZ $4.88
  • RMD $10.37
  • Revenue Next Year
  • XYZ $10.14
  • RMD $7.77
  • P/E Ratio
  • XYZ $16.73
  • RMD $28.63
  • Revenue Growth
  • XYZ 4.60
  • RMD 9.54
  • 52 Week Low
  • XYZ $44.27
  • RMD $188.56
  • 52 Week High
  • XYZ $99.26
  • RMD $263.05
  • Technical
  • Relative Strength Index (RSI)
  • XYZ N/A
  • RMD 53.77
  • Support Level
  • XYZ N/A
  • RMD $253.94
  • Resistance Level
  • XYZ N/A
  • RMD $259.49
  • Average True Range (ATR)
  • XYZ 0.00
  • RMD 3.77
  • MACD
  • XYZ 0.00
  • RMD -0.50
  • Stochastic Oscillator
  • XYZ 0.00
  • RMD 41.96

About XYZ BLOCK INC

Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2024, Square's payment volume was almost USD 250 million.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: